21 May 2013
Keywords: novartis, tasigna, shows, efficacy, glivec-resistant, ph, cml
Article | 18 December 2006
Swiss drug major Novartis says that data from a Phase II trial of its developmental anticancer agent Tasigna (nilotinib) demonstrate ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
18 December 2006
© 2013 thepharmaletter.com